Skip to main content
Equibles
MRNA logo

MRNA · Moderna, Inc.

Track MRNA — free

Use MRNA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$147.60 -3.21 (-2.13%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$59.43B
Shares
399.24M

MRNA metrics

71 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$150.81
Market cap
$59.43B

Price action

19 metrics
Price change (1W)
+0.8%
Price change (30D)
+164.6%
Price change (3M)
+207.4%
Price change (6M)
+160.9%
Price change (YTD)
+411.4%
Price change (1Y)
+523.4%
Trailing year
Price change (5Y)
-62.1%
52-week high
$174.38
52-week low
$22.36
Change from 52-week high
-13.5%
Change from 52-week low
+574.5%
Annualized volatility
192.1%
Beta
2.0
RSI (14D)
65.8
Price vs SMA 50
+83.9%
Price vs SMA 200
+181.4%
Avg volume (3M)
15.36M
Relative volume
1.1
Average dollar volume
$1.82B

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
399.24M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
27.1×
reciprocal yield 3.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
27.6×
reciprocal yield 3.6%
P / book
9.1
reciprocal yield 11.0%
FCF yield
-2.0%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-5.1%

Historical valuation

8 metrics
P / E historical average (3Y)
11.1×
reciprocal yield 9.0%
P / E historical average (5Y)
11.1×
reciprocal yield 9.0%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-31

Profitability

9 metrics
Gross margin
23.4%
Operating margin
-149.0%
Trailing 12 months
Net margin
-141.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$3.32B
Net income (TTM)
−$3.15B
Trailing 12 months
Diluted EPS (TTM)
$-7.98
FCF margin
-55.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-8.46

Growth

11 metrics
Revenue growth YoY
+2.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.23B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.6%
Year over year · more shares
Revenue CAGR (3Y)
-53.4%
Revenue CAGR (5Y)
+19.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-46.6%
Return on assets
-28.7%
Debt / equity
0.1
Current ratio
2.3
EBITDA (TTM)
−$3.09B
Free cash flow (TTM)
−$1.24B
Quick ratio
2.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.13B
Latest balance sheet
Cash & equivalents
$1.72B
Total assets
$10.96B
Total debt
$591.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.07B
Capital expenditures (TTM)
$171.00M
R&D (TTM)
$2.88B
SG&A (TTM)
—
Stock compensation (TTM)
$462.00M
R&D / revenue
129.1%
Stock compensation / revenue
20.7%

Ownership (13F)

3 metrics
13F filers
795
13F filer change QoQ
+53
Institutional ownership
90.4%

Short interest

3 metrics
Short interest
13.2%
Latest settlement · 9.2 days to cover
Days to cover
9.2d
Short-squeeze score
85 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$35.06M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1682852 CUSIP 60770K107 13F (30d) 504 filings 498 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)